Journal of vitreoretinal diseases · 2026
Pilot Clinical Trial of Topical Netarsudil to Lower Risk of Proliferative Vitreoretinopathy in High-Risk Primary Retinal Detachment.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Momenaei Bita, Ni Roselind, Zhang Jingwen, Yonekawa Yoshihiro, Kuriyan Ajay E, Sivalingam Meera D, Deaner Jordan D, Orlin Anton, Cohen Michael N, Klufas Michael A, Garg Sunir J, Ho Allen C, Xu David, Vander James F, Chiang Allen, Kaiser Richard S, Hsu Jason
Аннотация
PURPOSE: To determine whether a topical rho-kinase inhibitor used in eyes with primary rhegmatogenous retinal detachment (RRD) at high risk for proliferative vitreoretinopathy (PVR) reduces the rate of recurrent RD due to grade C or worse PVR.
METHODS: This randomized, double-masked, placebo-controlled trial (ClinicalTrials.gov: NCT05660447) included patients with primary RRD undergoing pars plana vitrectomy (PPV), with or without scleral buckling, who had 1 to 3 PVR risk factors: 3 or more breaks, 2 or more quadrants of RD, RD for longer than 3 weeks, vitreous hemorrhage, or choroidal detachment. Participants were randomized to netarsudil 0.02% or artificial tears, administered once daily for 8 weeks starting on postoperative day 1. The primary outcome was the rate of recurrent RD due to grade C PVR at 6 months.
RESULTS: A total of 79 patients were randomized (40 to netarsudil, 39 to placebo). After excluding dropouts and those lost to follow-up, 38 netarsudil and 34 placebo participants were analyzed. There was no significant difference in baseline high-risk features for PVR between the netarsudil and placebo arms. Eight eyes (21.1%) in the netarsudil arm vs 6 eyes (17.6%) in the placebo arm developed redetachment (P = .77), with 4 vs 6 of the redetachments due to PVR (10.5% vs 17.6%; P = .5). At 6 months, epiretinal membrane was found in 55.2% of eyes in the netarsudil group and in 63.6% in the placebo group (P > .99). Median logMAR (Snellen equivalent) visual acuity in the netarsudil vs placebo arm was 1.24 (20/350) vs 1.35 (20/450) at baseline (P = .87), 0.7 (20/100) vs 0.48 (20/60) at month 3 (P = .27), and 0.48 (20/60) vs 0.54 (20/70) at month 6 (P = .91).
CONCLUSIONS: Treatment of eyes with primary RRD at high risk for PVR with netarsudil 0.02% once daily for 8 weeks after PPV with or without scleral buckling did not appear to affect PVR redetachment or visual outcomes compared with placebo.
METHODS: This randomized, double-masked, placebo-controlled trial (ClinicalTrials.gov: NCT05660447) included patients with primary RRD undergoing pars plana vitrectomy (PPV), with or without scleral buckling, who had 1 to 3 PVR risk factors: 3 or more breaks, 2 or more quadrants of RD, RD for longer than 3 weeks, vitreous hemorrhage, or choroidal detachment. Participants were randomized to netarsudil 0.02% or artificial tears, administered once daily for 8 weeks starting on postoperative day 1. The primary outcome was the rate of recurrent RD due to grade C PVR at 6 months.
RESULTS: A total of 79 patients were randomized (40 to netarsudil, 39 to placebo). After excluding dropouts and those lost to follow-up, 38 netarsudil and 34 placebo participants were analyzed. There was no significant difference in baseline high-risk features for PVR between the netarsudil and placebo arms. Eight eyes (21.1%) in the netarsudil arm vs 6 eyes (17.6%) in the placebo arm developed redetachment (P = .77), with 4 vs 6 of the redetachments due to PVR (10.5% vs 17.6%; P = .5). At 6 months, epiretinal membrane was found in 55.2% of eyes in the netarsudil group and in 63.6% in the placebo group (P > .99). Median logMAR (Snellen equivalent) visual acuity in the netarsudil vs placebo arm was 1.24 (20/350) vs 1.35 (20/450) at baseline (P = .87), 0.7 (20/100) vs 0.48 (20/60) at month 3 (P = .27), and 0.48 (20/60) vs 0.54 (20/70) at month 6 (P = .91).
CONCLUSIONS: Treatment of eyes with primary RRD at high risk for PVR with netarsudil 0.02% once daily for 8 weeks after PPV with or without scleral buckling did not appear to affect PVR redetachment or visual outcomes compared with placebo.